Rachel Phillips
@rachpips.bsky.social
160 followers 160 following 70 posts
Senior Lecturer in Medical Statistics and Clinical Trials, Imperial College London.
Posts Media Videos Starter Packs
Pinned
rachpips.bsky.social
🔈Announcing a series of webinars showcasing our 2024 Trials Adverse Event Special Series.

Over the course of 2025 we have a range of talks lined up covering trial conduct, analysis, reporting, and public involvement.

Please register your interest here: forms.microsoft.com/e/qqNgLTP651
Microsoft Forms
forms.microsoft.com
Reposted by Rachel Phillips
richardhooper.bsky.social
I'm doing a webinar in two weeks (15 Oct 1-2pm BST), part of NIHR Research Support Service's Methods Academy series, on the age-old question: should I do a stepped wedge trial?

Free registration, details here: tinyurl.com/z6cjvce3

@nihr-rss.bsky.social @wiphcem.bsky.social @qmul-wiph.bsky.social
Reposted by Rachel Phillips
rachpips.bsky.social
They discuss how often "the apparent benefits of pharmacological interventions are less impressive, and more information emerges about harms they can cause" when using the CSR. You can read the full papers here: www.biomedcentral.com/collections/...
The collection, analysis and reporting of adverse events in randomised controlled trials
www.biomedcentral.com
rachpips.bsky.social
In our latest adverse event webinar Jeffrey Aronson & Igho Onakpoya discuss their review that looked at how data from clinical study reports compare with data in published trial reports. Catch-up on their talk here: www.statsci.co.uk/webinar-series
WEBINARS | StatsCI
www.statsci.co.uk
Reposted by Rachel Phillips
imperialctu.bsky.social
And that's a wrap on this year's NIHR undergraduate internships. It's been a pleasure hosting three rising stars, they've each achieved so much in just 8 weeks. We can't wait to see what the future holds for them. Congratulations Alex, Mahima & Joe and good luck with the rest of your studies.
Reposted by Rachel Phillips
suziecro.bsky.social
Are estimands being correctly used?
A new review of protocols led by Timothy Clark shows many incorrectly defined estimand attributes. See the top areas for improvement & full results here:
trialsjournal.biomedcentral.com/articles/10.... #Trials
rachpips.bsky.social
Thurs 4th September is the next webinar in our adverse event special series. Jeffrey Aronson & Igho Onakpoya will present their review of Clinical Study Reports & discuss the insights they offer when trying to quantify intervention benefits & harms. Sign up here:
lnkd.in/ebMSPhds
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
Reposted by Rachel Phillips
imperialctu.bsky.social
Join us for Professor Victoria Cornelius' inaugural lecture - Under pressure: smarter trials for better health outcomes
Thursday, 30 October 2025 17.30 - 18.30 GMT
Register here: www.imperial.ac.uk/events/19688...
Under pressure: smarter trials for better health outcomes
Join us for Professor Victoria Cornelius' inaugural lecture in person or online.
www.imperial.ac.uk
Reposted by Rachel Phillips
statsci.bsky.social
Attending the International Society for Clinical Biostatistics this week?

Don’t miss

@ellievanvogt.bsky.social and Xiao Xuan

who will be presenting these exciting topics:
rachpips.bsky.social
Don't miss this exciting opportunity to join us at @imperialctu.bsky.social @statsci.bsky.social. Closing 28th August 2025
statsci.bsky.social
🔊We're hiring!
Imperial Clinical Trials Unit are looking for an ambitious senior statistician with experience in clinical trials & design & analysis of adaptive trials to lead a research programme in antimicrobial resistance & data-enabled trials.
Full details: www.imperial.ac.uk/jobs/search-...
Description
Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...
www.imperial.ac.uk
Reposted by Rachel Phillips
statsci.bsky.social
Meet Alex Dixon, who is spending his summer experiencing life within ICTUs statistics and trial methodology group and conducting a research project with us as part of an NIHR undergraduate internship

Find out what he has been up to here:
www.statsci.co.uk/news
Reposted by Rachel Phillips
statsci.bsky.social
🔊We're hiring!
Imperial Clinical Trials Unit are looking for an ambitious senior statistician with experience in clinical trials & design & analysis of adaptive trials to lead a research programme in antimicrobial resistance & data-enabled trials.
Full details: www.imperial.ac.uk/jobs/search-...
Description
Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...
www.imperial.ac.uk
rachpips.bsky.social
🔊We're hiring! We are looking for an ambitious senior statistician with experience in clinical trials and the design and analysis of adaptive trials to lead a research programme in antimicrobial resistance and support colleagues in data-enabled trials. Full details: lnkd.in/eWpwsH6s
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
rachpips.bsky.social
Inga Frantz & Nina Heinrichs discuss development of a comprehensive adverse event assessment tool based on their experiences in the RISE project, a multisite RCT that evaluated a parenting intervention for parents of children with increased levels of behaviour problems.
rachpips.bsky.social
Catch-up on today's adverse event webinar here: www.statsci.co.uk/webinar-series
rachpips.bsky.social
Next week we continue our adverse event special series. On Thursday 3rd July 1pm (BST), we host Inga Frantz who will be discussing their paper demonstrating the development and testing of a tool to assess the systematic collection of AEs in parenting intervention studies.
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
Reposted by Rachel Phillips
statsci.bsky.social
Attending #PSI2025 at Wembley stadium ⚽ this week? Don’t miss new research on a novel multiple imputation procedure for handling missing data in clinical trials targeting a treatment policy estimand by @suziecro.bsky.social James Roger & James Carpenter
rachpips.bsky.social
Suggesting that core harm outcomes along with serious, related and unexpected adverse events (SAEs, SARs, SUSARs), any pre-specified events, and events that lead to discontinuation of the treatment should always be reported. Seems there is still lots of room for improvement.
rachpips.bsky.social
This highlights there's still a need for an agreed consensus on what should be reported in journal articles. @vcornelius.bsky.social called for this in their 2022 JCE article doi.org/10.1016/j.jc...
Redirecting
doi.org